Sector News

CVC talks Alvogen sale with Shanghai

September 26, 2017
Life sciences

Amid a wave of consolidation prompted by pricing pressures on the generics industry, another sale is brewing.

The private equity owners of Alvogen—which include CVC Capital Partners—are weighing their options for the New Jersey drugmaker, which could be valued at about $4 billion, Bloomberg reports. And a sale of Alvogen’s U.S. business to Shanghai Pharmaceuticals Holding Co. is on the table.

CVC and its fellow controlling shareholders—who nabbed their stake in a 2015 deal that valued Alvogen at $2 billion—have held on-and-off talks with Shanghai, the news service notes. Though while they’re not formally putting the company up for auction, they may hold talks with other international suitors.

Under a potential Shanghai transaction, Alvogen would hang onto its operations in Asia and Europe, which include Alvogen Korea Co., a plant in Romania, and a packaging center in Serbia. Shanghai, though, would pick up Alvogen’s biggest market, where it sells generics in therapeutic areas such as oncology, cardiology and neurology and provides third-party services including contract manufacturing in clinical research.

For Shanghai, the buy would be a boost in the wake of a failed play for German generics maker Stada, which is going through the sale process with private equity partners Bain Capital and Cinven. Sources have told Bloomberg the company is also currently bidding for a stake in Atlanta’s Arbor Pharmaceuticals and Cardinal Health’s Chinese distribution business.

For years, Alvogen, launched and helmed by former Actavis executive Robert Wessman, has said it’s angling to become a top-tier generics player. The CVC-led deal seemed to further that aim, with Wessman touting his company’s new access to “significant experience and additional resources” to pump up growth.

Times have grown increasingly tough for generics competitors over the last couple of years, prompting some, such as Stada, to consider selling. Others—particularly in the industry’s top ranks—have gone for scale instead and made buys of their own, with Teva forking over $40.5 billion for Allergan’s generics arm and Mylan shelling out $5.7 billion for Abbott Laboratories’ ex-U.S. copycat business.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach